Top

Journal of Endocrinological Investigation

Published in:

01-02-2016 | Original Article

Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis

Authors: S. Görar, E. Ademoğlu, A. Çarlıoğlu, B. Alioğlu, H. Bekdemir, B. Sağlam, Z. Candan, R. Üçler, C. Culha, Y. Aral

Published in: Journal of Endocrinological Investigation | Issue 2/2016

Abstract

Purpose

Chemokines play an important role in the pathogenesis of autoimmune thyroid diseases. Platelet factor 4 (PF4, CXCL4) released from activated platelets is a chemokine. However, its clinical importance in autoimmune thyroiditis remains unknown. This study is intended to determine circulating levels of PF4 levels in patients with autoimmune thyroiditis (AIT).

Methods

Circulating levels of PF4 were measured in 34 consecutive patients with newly diagnosed AIT and 18 euthyroid controls. Among AIT group, 16 patients were euthyroid and 18 had subclinic hypothyroidism. Controls and individuals with AIT were similar in terms of age.

Results

Serum levels of PF4 were comparable in patients with AIT and in controls. Among patients with AIT, PF4 was significantly lower in those with subclinical hypothyroidism than in euthyroid individuals (p = 0.001). In correlation analysis, PF4 was negatively correlated with TSH (r = −0.663, p = 0.000) and positively correlated with free T₄ (r = 0.428, p = 0.012). There was not any significant correlation between PF4 and AbTPO, AbTg.

Conclusion

The present study demonstrated for the first time that circulating PF4 levels are decreased in subclinically hypothyroid AIT. This result draws attention to the circulating PF4 levels in subclinically hypothyroid AIT and may shed light on further researches at this topic.

Cooper DS, Greenspan FS, Ladenson PW (2007) The thyroid gland. In: Gardner DG, Shoback D (eds) Basic and clinical endocrinology, 8th edn. Lange, New York, pp 264–265

Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP (2003) Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 59:207–213CrossRef

Mikoś H, Mikoś M, Obara-Moszyńska M, Niedziela M (2014) The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol 65:150–155PubMedCrossRef

Weetman AP, Bennett GL, Wong WL (1992) Thyroid follicular cells produce interleukin-8. J Clin Endocrinol Metab 75:328–330PubMed

Fang Y, Zhao L, Yan F (2010) Chemokines as novel therapeutic targets in autoimmune thyroiditis. Recent Pat DNA Gene Seq 4:52–57PubMedCrossRef

Pilatova K, Greplova K, Demlova R, Bencsikova B, Klement GL, Zdrazilova-Dubska L (2013) Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology. J Hematol Oncol 6:42PubMedPubMedCentralCrossRef

Jenne CN, Urrutia R, Kubes P (2013) Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol 35:254–261PubMedCrossRef

Sakr Y (2011) Heparin-induced thrombocytopenia in the ICU: an overview. Crit Care 15:211PubMedPubMedCentralCrossRef

Rotondi M, Coperchini F, Pignatti P, Sideri R, Gropelli G, Leporati P, Manna L et al (2013) Interferon γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: first step toward a differentiation between autoimmune and tumor-related inflammation? J Clin Endocrinol Metab 98:308–313PubMedCrossRef

10.

Dumenco LL, Everson B, Culp LA, Ratnoff OD (1988) Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. J Lab Clin Med 112:394–400PubMed

11.

Yang L, Rezaie AR (2007) Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. Thromb Haemost 97:899–906PubMed

12.

Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ et al (2003) Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 102:146–151PubMedCrossRef

13.

Thachil J (2010) The prothrombotic potential of platelet factor 4. Eur J Intern Med 21:79–83PubMedCrossRef

14.

Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt E et al (2002) Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. Immunol 169:770–777CrossRef

15.

Kasperska-Zajac A, Brzoza Z, Rogala B (2006) Circulating level of the platelet-derived CXC chemokine platelet factor 4 in chronic urticaria patients with or without coexistent euthyroid Hashimoto’s thyroiditis. Autoimmunity 39:265–268PubMedCrossRef

16.

Rotondi M, Coperchini F, Chiovato L (2013) CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice. Cytokine Growth Factor Rev 24:539–546PubMedCrossRef

17.

Liu C, Papewalis C, Domberg J, Scherbaum WA, Schott M (2008) Chemokines and autoimmune thyroid diseases. Horm Metab Res 40:361–368PubMedCrossRef

18.

Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A et al (2004) High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496–5499PubMedCrossRef

19.

Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L et al (2005) Increase of interferon- γ inducible a chemokine CXCL10 but not β chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152:171–177PubMedCrossRef

20.

Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P et al (2011) Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 96:1859–1863PubMedCrossRef

21.

Domberg J, Liu C, Papewalis C, Pfleger C, Xu K, Willenberg HS et al (2008) Circulating chemokines in patients with autoimmune thyroid diseases. Horm Metab Res 40:416–421PubMedCrossRef

Title: Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis
Authors: S. Görar
E. Ademoğlu
A. Çarlıoğlu
B. Alioğlu
H. Bekdemir
B. Sağlam
Z. Candan
R. Üçler
C. Culha
Y. Aral
Publication date: 01-02-2016
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 2/2016
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0348-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2016

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

d-Aspartic acid stimulates steroidogenesis through the delay of LH receptor internalization in a mammalian Leydig cell line

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly

Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes

Antonello da Messina: Virgin Annunciate

Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials